Incyte Corporation (INCY) Insider Trading

Last 12 months

Insiders sold $58.3M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Feb 2022.

Net open-market

−$58.3M

0 buys · 29 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 10

executives and directors

Last open-market buy

Feb 2022

Feb 22, 2022

Get an email when INCY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	2,642	$112.71	$298k	1.4%	Form 4
Sep 15	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan 2 parts	23,218	$120.49 average	$2.8M	11%	Form 4
Aug 19	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	10,801	$125.56	$1.36M	5.6%	Form 4
Aug 12	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	10,803	$120.04	$1.3M	5.3%	Form 4
Aug 5	Patrick A Mayes EVP & Chief Scientific Officer	Sold10b5-1 plan	2,207	$123.99	$274k	3.5%	Form 4
Aug 5	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	10,640	$122.69	$1.31M	4.9%	Form 4
Jul 31 – Aug 3	Patrick A Mayes EVP & Chief Scientific Officer	Sold10b5-1 plan 12 parts	47,954	$119.58 average	$5.73M	44%	Form 4
Jul 31	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	15,888	$119.70	$1.9M	6.9%	Form 4
Jul 16	Mohamed Khairie Issa EVP, Head of U.S. Commercial	Sold10b5-1 plan	1,093	$115.01	$126k	1.5%	Form 4
Jul 16	Steven H Stein CMO & Head of Late-Stage Dev.	Sold10b5-1 plan	1,877	$114.73	$215k	5.7%	Form 4
Jul 15	Steven H Stein CMO & Head of Late-Stage Dev.	Sold10b5-1 plan	28,237	$113.05	$3.19M	55%	Form 4
Jun 4	Thomas Tray Principal Accounting Officer	Sold10b5-1 plan	2,639	$100.00	$264k	11%	Form 4
May 26	Thomas Tray Principal Accounting Officer	Sold10b5-1 plan	2,051	$97.35	$200k	8.8%	Form 4
May 19	Paul J Clancy Director	Sold10b5-1 plan	15,000	$94.93	$1.42M	39%	Form 4
Apr 17	Pablo J Cagnoni President, Global Head of R&D	Sold10b5-1 plan	18,667	$96.50	$1.8M	6.6%	Form 4
Mar 17	Pablo J Cagnoni President, R&D	Sold10b5-1 plan	18,667	$94.24	$1.76M	7.4%	Form 4
Feb 19	Pablo J Cagnoni President, R&D	Sold10b5-1 plan	18,668	$100.91	$1.88M	7.4%	Form 4
Jan 7	Mohamed Khairie Issa EVP, Head of US Oncology	Sold10b5-1 plan	10,856	$109.07	$1.18M	14%	Form 4
Jan 5	Steven H Stein EVP & Chief Medical Officer	Sold10b5-1 plan	15,634	$101.70	$1.59M	31%	Form 4
Dec 18, 2025 – Dec 19, 2025	Thomas Tray Principal Accounting Officer	Sold10b5-1 plan 2 parts	3,374	$99.69 average	$336k	13%	Form 4
Dec 16, 2025 – Dec 17, 2025	Michael James Morrissey EVP, Head of Tech. Operations	Sold10b5-1 plan 3 parts	58,331	$97.29 average	$5.68M	68%	Form 4
Dec 10, 2025 – Dec 11, 2025	Patrick A Mayes EVP & Chief Scientific Officer	Sold10b5-1 plan 2 parts	5,808	$95.55 average	$555k	8.8%	Form 4
Dec 1, 2025 – Dec 2, 2025	Steven H Stein EVP & Chief Medical Officer	Sold10b5-1 plan 2 parts	22,664	$102.56 average	$2.32M	26%	Form 4
Nov 21, 2025 – Nov 24, 2025	Thomas Tray Principal Accounting Officer	Sold10b5-1 plan 2 parts	769	$102.78 average	$79k	3.2%	Form 4
Nov 17, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	278	$104.36	$29k	1.0%	Form 4
Nov 10, 2025	Herve Hoppenot Director	Sold10b5-1 plan	187,500	$105.46	$19.8M	36%	Form 4
Nov 5, 2025	Steven H Stein EVP & Chief Medical Officer	Sold10b5-1 plan	5,233	$102.20	$535k	4.8%	Form 4
Nov 4, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	598	$101.36	$61k	2.2%	Form 4
Nov 3, 2025	Lee Heeson EVP, Head of Incyte Intl	Sold10b5-1 plan	3,074	$94.02	$289k	9.5%	Form 4
Oct 15, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	277	$85.13	$24k	1.0%	Form 4
Oct 2, 2025 – Oct 3, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan 2 parts	4,100	$85.85 average	$352k	13%	Form 4
Sep 16, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	278	$83.15	$23k	0.8%	Form 4
Sep 2, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	598	$84.97	$51k	1.8%	Form 4
Aug 15, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	277	$86.81	$24k	0.8%	Form 4
Aug 4, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan	598	$75.77	$45k	1.8%	Form 4
Jul 21, 2025	Steven H Stein EVP & Chief Medical Officer	Sold10b5-1 plan	3,706	$67.94	$252k	3.5%	Form 4
Jul 16, 2025	Barry P Flannelly EVP & General Manager US	Sold10b5-1 plan	1,340	$68.36	$92k	3.7%	Form 4
Jul 16, 2025	Vijay K Iyengar EVP, GMAPPS	Sold10b5-1 plan	983	$68.36	$67k	2.4%	Form 4
Jul 15, 2025 – Jul 16, 2025	Sheila A. Denton EVP & General Counsel	Sold10b5-1 plan 2 parts	4,115	$69.57 average	$286k	11%	Form 4
Jul 15, 2025	Vijay K Iyengar EVP, GMAPPS	Sold10b5-1 plan	1,177	$69.86	$82k	2.8%	Form 4

Oct 1510b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 2,642 at $112.71
$298k
1.4% of stake
Sep 1510b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 23,218 at avg $120.49
$2.8M
11% of stake
Aug 1910b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 10,801 at $125.56
$1.36M
5.6% of stake
Aug 1210b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 10,803 at $120.04
$1.3M
5.3% of stake
Aug 510b5-1 plan
Patrick A Mayes
EVP & Chief Scientific Officer · sold 2,207 at $123.99
$274k
3.5% of stake
Aug 510b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 10,640 at $122.69
$1.31M
4.9% of stake
Jul 31 – Aug 310b5-1 plan
Patrick A Mayes
EVP & Chief Scientific Officer · sold 47,954 at avg $119.58
$5.73M
44% of stake
Jul 3110b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 15,888 at $119.70
$1.9M
6.9% of stake
Jul 1610b5-1 plan
Mohamed Khairie Issa
EVP, Head of U.S. Commercial · sold 1,093 at $115.01
$126k
1.5% of stake
Jul 1610b5-1 plan
Steven H Stein
CMO & Head of Late-Stage Dev. · sold 1,877 at $114.73
$215k
5.7% of stake
Jul 1510b5-1 plan
Steven H Stein
CMO & Head of Late-Stage Dev. · sold 28,237 at $113.05
$3.19M
55% of stake
Jun 410b5-1 plan
Thomas Tray
Principal Accounting Officer · sold 2,639 at $100.00
$264k
11% of stake
May 2610b5-1 plan
Thomas Tray
Principal Accounting Officer · sold 2,051 at $97.35
$200k
8.8% of stake
May 1910b5-1 plan
Paul J Clancy
Director · sold 15,000 at $94.93
$1.42M
39% of stake
Apr 1710b5-1 plan
Pablo J Cagnoni
President, Global Head of R&D · sold 18,667 at $96.50
$1.8M
6.6% of stake
Mar 1710b5-1 plan
Pablo J Cagnoni
President, R&D · sold 18,667 at $94.24
$1.76M
7.4% of stake
Feb 1910b5-1 plan
Pablo J Cagnoni
President, R&D · sold 18,668 at $100.91
$1.88M
7.4% of stake
Jan 710b5-1 plan
Mohamed Khairie Issa
EVP, Head of US Oncology · sold 10,856 at $109.07
$1.18M
14% of stake
Jan 510b5-1 plan
Steven H Stein
EVP & Chief Medical Officer · sold 15,634 at $101.70
$1.59M
31% of stake
Dec 18, 2025 – Dec 19, 202510b5-1 plan
Thomas Tray
Principal Accounting Officer · sold 3,374 at avg $99.69
$336k
13% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Michael James Morrissey
EVP, Head of Tech. Operations · sold 58,331 at avg $97.29
$5.68M
68% of stake
Dec 10, 2025 – Dec 11, 202510b5-1 plan
Patrick A Mayes
EVP & Chief Scientific Officer · sold 5,808 at avg $95.55
$555k
8.8% of stake
Dec 1, 2025 – Dec 2, 202510b5-1 plan
Steven H Stein
EVP & Chief Medical Officer · sold 22,664 at avg $102.56
$2.32M
26% of stake
Nov 21, 2025 – Nov 24, 202510b5-1 plan
Thomas Tray
Principal Accounting Officer · sold 769 at avg $102.78
$79k
3.2% of stake
Nov 17, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 278 at $104.36
$29k
1.0% of stake
Nov 10, 202510b5-1 plan
Herve Hoppenot
Director · sold 187,500 at $105.46
$19.8M
36% of stake
Nov 5, 202510b5-1 plan
Steven H Stein
EVP & Chief Medical Officer · sold 5,233 at $102.20
$535k
4.8% of stake
Nov 4, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 598 at $101.36
$61k
2.2% of stake
Nov 3, 202510b5-1 plan
Lee Heeson
EVP, Head of Incyte Intl · sold 3,074 at $94.02
$289k
9.5% of stake
Oct 15, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 277 at $85.13
$24k
1.0% of stake
Oct 2, 2025 – Oct 3, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 4,100 at avg $85.85
$352k
13% of stake
Sep 16, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 278 at $83.15
$23k
0.8% of stake
Sep 2, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 598 at $84.97
$51k
1.8% of stake
Aug 15, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 277 at $86.81
$24k
0.8% of stake
Aug 4, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 598 at $75.77
$45k
1.8% of stake
Jul 21, 202510b5-1 plan
Steven H Stein
EVP & Chief Medical Officer · sold 3,706 at $67.94
$252k
3.5% of stake
Jul 16, 202510b5-1 plan
Barry P Flannelly
EVP & General Manager US · sold 1,340 at $68.36
$92k
3.7% of stake
Jul 16, 202510b5-1 plan
Vijay K Iyengar
EVP, GMAPPS · sold 983 at $68.36
$67k
2.4% of stake
Jul 15, 2025 – Jul 16, 202510b5-1 plan
Sheila A. Denton
EVP & General Counsel · sold 4,115 at avg $69.57
$286k
11% of stake
Jul 15, 202510b5-1 plan
Vijay K Iyengar
EVP, GMAPPS · sold 1,177 at $69.86
$82k
2.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch INCY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Commercial Physical & Biological Research

CRLCharles River Laboratories International, Inc.

MEDPMedpace Holdings Inc.

IQVIQVIA Holdings Inc.

Spot a number that looks wrong? Check it in INCY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing INCY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.